Assenagon Asset Management S.A. Boosts Stake in Intra-Cellular Therapies,

☀️Trending News

INTRA-CELLULAR ($NASDAQ:ITCI): Intra-Cellular Therapies, Inc. is a biopharmaceutical company that focuses on developing novel treatments for neuropsychiatric and neurodegenerative disorders. The company’s main focus is on developing therapies for schizophrenia and other central nervous system disorders. As a relatively new company, Intra-Cellular Therapies has been gaining attention from investors and analysts for its promising drug pipeline. Recently, Assenagon Asset Management S.A., a prominent asset management firm, has increased its stake in Intra-Cellular Therapies. This move signals a strong belief in the company’s potential and future growth. As of their latest filing, Assenagon now holds over 1 million shares in Intra-Cellular Therapies, making it one of the company’s largest institutional shareholders. This boost in stake by Assenagon comes at a critical time for Intra-Cellular Therapies. The company recently announced positive results from its Phase 3 clinical trial for its lead drug candidate, lumateperone.

This drug has shown promising efficacy in treating schizophrenia and has the potential to become a game-changer in the treatment of this disorder. With Assenagon’s increased investment, Intra-Cellular Therapies now has more capital to fuel its research and development efforts. This will likely speed up the timeline for lumateperone’s potential approval and commercialization. It also shows confidence in the company’s management and strategy, which could attract more investors and drive up the stock price. In addition to lumateperone, Intra-Cellular Therapies has several other drug candidates in its pipeline for various neuropsychiatric and neurodegenerative disorders. The company’s focus on developing innovative and effective treatments makes it an attractive investment opportunity for long-term growth. With promising clinical data and strong financial backing, Intra-Cellular Therapies is poised for growth in the biopharmaceutical industry.

Price History

This news comes after the company’s stock saw a significant rise on Wednesday, with the opening price at $67.9 and closing price at $69.7. This marks a 3.6% increase from the previous day’s closing price of $67.3. The boost in Assenagon’s stake demonstrates their confidence in Intra-Cellular Therapies and its potential for growth. As a specialized asset management firm, Assenagon’s investment decisions are carefully selected and their increased stake in the company is a strong indication of their belief in its future success. Intra-Cellular Therapies has been making significant strides in the biopharmaceutical industry, particularly in the development of therapies for central nervous system disorders such as schizophrenia and bipolar disorder. Their lead product candidate, lumateperone, is currently in late-stage clinical trials and has shown promising results in treating these conditions.

The company also has a robust pipeline of other potential treatments in various stages of development. This boost in stake by Assenagon also reflects the overall positive sentiment surrounding Intra-Cellular Therapies’ stock. This is a testament to the confidence of both investors and industry experts in the company’s potential for growth and success. In conclusion, the news of Assenagon Asset Management S.A.’s increased stake in Intra-Cellular Therapies serves as a positive indicator for the company’s prospects. With their promising product pipeline and growing interest from investors, Intra-Cellular Therapies is poised to make significant advancements in the field of central nervous system disorder treatments. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Intra-cellular Therapies. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Intra-cellular Therapies. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Intra-cellular Therapies. More…

Key Ratios Snapshot

Some of the financial key ratios for Intra-cellular Therapies are shown below. More…

Analysis

After conducting a thorough analysis of INTRA-CELLULAR THERAPIES‘s financials, I can conclude that the company is classified as a ‘cheetah’, according to our Star Chart categorization. This means that INTRA-CELLULAR THERAPIES has achieved high revenue or earnings growth, but is considered less stable due to lower profitability. This type of company may attract investors who are seeking growth and are willing to take on a slightly higher level of risk. Looking at INTRA-CELLULAR THERAPIES’s financial metrics, the company appears to be strong in terms of its assets and growth potential. However, it may not be as attractive to investors looking for immediate returns through dividends, as its dividend performance is weaker. Additionally, INTRA-CELLULAR THERAPIES’s profitability may not be as strong as other companies in the market, which is something investors should consider when making investment decisions. In terms of health score, INTRA-CELLULAR THERAPIES receives an intermediate rating of 5/10. This takes into account the company’s cashflows and debt, and suggests that it is likely to safely ride out any crisis without the risk of bankruptcy. This may provide some reassurance to potential investors, as the company appears to have a stable financial position. Overall, INTRA-CELLULAR THERAPIES may be a good fit for investors who are interested in companies with strong assets and growth potential, and are comfortable with taking on a slightly higher level of risk. However, those seeking immediate returns through dividends may not find this company as appealing. With an intermediate health score, INTRA-CELLULAR THERAPIES appears to be in a relatively stable position and may be a suitable option for those looking for long-term investments. More…

Peers

The company’s lead product candidate, lumateperone, is in Phase III clinical trials for the treatment of schizophrenia. SCYNEXIS Inc, Invion Ltd, and Shuttle Pharmaceuticals Holdings Inc are all clinical stage biopharmaceutical companies that focus on the development of small molecule drugs for the treatment of neuropsychiatric disorders.

– SCYNEXIS Inc ($NASDAQ:SCYX)

SCYNEXIS Inc is a biopharmaceutical company that focuses on the development and commercialization of oral and intravenous anti-infective agents to treat patients with serious and life-threatening infections. The company’s lead product, SCY-078, is a novel, first-in-class oral and intravenous agent in clinical development for the treatment of serious fungal infections. The company’s second product, SCY-123, is an oral agent in clinical development for the treatment of bacterial infections, including Clostridium difficile infection.

– Invion Ltd ($ASX:IVX)

Invion Ltd is a development stage biopharmaceutical company, which focuses on the treatment of cancer and inflammatory disease. The company was founded in 2003 and is headquartered in Brisbane, Australia.

– Shuttle Pharmaceuticals Holdings Inc ($NASDAQ:SHPH)

Shuttle Pharmaceuticals Holdings Inc is a pharmaceutical company with a market cap of 25.81M as of 2022. The company has a Return on Equity of 47.66%. Shuttle Pharmaceuticals Holdings Inc is engaged in the research, development, manufacture, and sale of pharmaceutical products. The company’s products include prescription and over-the-counter drugs, as well as nutritional supplements and other health-related products.

Summary

Assenagon Asset Management S.A. recently increased its holdings in Intra-Cellular Therapies, Inc., a biopharmaceutical company that focuses on developing treatments for neurological and psychiatric disorders. This move likely reflects the investment firm’s confidence in the company’s potential for growth and success.

Additionally, the stock price for Intra-Cellular Therapies experienced a significant increase on the same day, potentially signaling positive sentiment among investors. This could be attributed to recent developments or news surrounding the company, as well as potential future prospects. Overall, Assenagon Asset Management S.A.’s investment in Intra-Cellular Therapies and the rise in stock price could be seen as a positive sign for the company’s future performance.